dc.contributor.author | Paraboschi, I | |
dc.contributor.author | Turnock, S | |
dc.contributor.author | Kramer-Marek, G | |
dc.contributor.author | Musleh, L | |
dc.contributor.author | Barisa, M | |
dc.contributor.author | Anderson, J | |
dc.contributor.author | Giuliani, S | |
dc.date.accessioned | 2021-06-11T12:58:20Z | |
dc.date.available | 2021-06-11T12:58:20Z | |
dc.date.issued | 2021-05-01 | |
dc.identifier.citation | Critical reviews in oncology/hematology, 2021, 161 pp. 103325 - ? | |
dc.identifier.issn | 1040-8428 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/4631 | |
dc.identifier.eissn | 1879-0461 | |
dc.identifier.doi | 10.1016/j.critrevonc.2021.103325 | |
dc.description.abstract | Near-InfraRed PhotoImmunoTherapy (NIR-PIT) is a novel cancer-targeted treatment effected by a chemical conjugation between a photosensitiser (e.g. the NIR phthalocyanine dye IRDye700DX) and a cancer-targeting moiety (e.g. a monoclonal antibody, moAb). Delivery of a conjugate in vivo leads to accumulation at the tumour cell surface by binding to cell surface receptors or antigens. Upon deployment of focal NIR-light, irradiation of the conjugate results in a rapid, targeted cell death. However, the mechanisms of action to produce the cytotoxic effects have yet to be fully understood. Herein, we bring together the current knowledge of NIR-PIT from preclinical and clinical studies in a variety of cancers highlighting the key unanswered research questions. Furthermore, we discuss how to enhance the local control of solid cancers using this novel treatment regimen. | |
dc.format | Print-Electronic | |
dc.format.extent | 103325 - ? | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | ELSEVIER SCIENCE INC | |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0 | |
dc.subject | Cell Line, Tumor | |
dc.subject | Humans | |
dc.subject | Neoplasms | |
dc.subject | Photosensitizing Agents | |
dc.subject | Antibodies, Monoclonal | |
dc.subject | Immunoconjugates | |
dc.subject | Immunotherapy | |
dc.subject | Phototherapy | |
dc.title | Near-InfraRed PhotoImmunoTherapy (NIR-PIT) for the local control of solid cancers: Challenges and potentials for human applications. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2021-03-26 | |
rioxxterms.version | VoR | |
rioxxterms.versionofrecord | 10.1016/j.critrevonc.2021.103325 | |
rioxxterms.licenseref.uri | https://creativecommons.org/licenses/by/4.0 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | Critical reviews in oncology/hematology | |
pubs.notes | Not known | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Preclinical Molecular Imaging | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Preclinical Molecular Imaging | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Preclinical Molecular Imaging | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Preclinical Molecular Imaging | |
pubs.publication-status | Published | |
pubs.volume | 161 | |
pubs.embargo.terms | Not known | |
icr.researchteam | Preclinical Molecular Imaging | |
icr.researchteam | Preclinical Molecular Imaging | |
dc.contributor.icrauthor | Turnock, Stephen | |
dc.contributor.icrauthor | Kramer-Marek, Gabriela | |